β-Adrenergic receptor expression in vascular tumors

Modern Pathology

Volumn 25, Issue 11, 2012, Pages 1446-1451

  Chisholm, Karen M ^a   Chang, Kay W ^a   Truong, Mai T ^a   Kwok, Shirley ^a   West, Rob B ^a   Heerema Mckenney, Amy E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunohistochemistry; infantile hemangiomas; tissue microarray; vascular; adrenergic

Indexed keywords

EID: 84868505891     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.108     Document Type: Article

References (30)

1. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003;48:477-493 quiz 494-6. (Pubitemid 36397008)
2. Bennett ML, Fleischer Jr AB, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001;137:1208-1213. (Pubitemid 32847844)
3. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
4. Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function-and life-threatening infantile hemangioma. Arch Pediatr 2004;11:99-107. (Pubitemid 38220704)
5. Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 1995;333:69.
6. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001;36:1273-1276. (Pubitemid 32705723)
7. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104:1616-1623. (Pubitemid 29510480)
8. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 1999;135:782-785. (Pubitemid 30180434)
9. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132:527-530. (Pubitemid 28180264)
10. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-2651. (Pubitemid 351831393)
11. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg 2009;123:195e-196e.
12. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:e423-e431.
13. Buckmiller LM. Propranolol treatment for infantile hemangiomas. Curr Opin Otolaryngol Head Neck Surg 2009;17:458-459.
14. Holmes WJ, Mishra A, Gorst C, et al. Propranolol as first-line treatment for infantile hemangiomas. Plast Reconstr Surg 2010;125:420-421.
15. Fulkerson DH, Agim NG, Al-Shamy G, et al. Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review. Childs Nerv Syst 2010;26:1799-1805.
16. Buckmiller LM, Munson PD, Dyamenahalli U, et al. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope 2010;120:676-681.
17. Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010;156: 335-338.
18. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-356. (Pubitemid 32476119)
19. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997;67:353-366. (Pubitemid 27509471)
20. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-274.
21. Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005;97:1182-1189.
22. Summers RJ, Kompa A, Roberts SJ. Beta-adrenoceptor subtypes and their desensitization mechanisms. J Auton Pharmacol 1997;17:331-343. (Pubitemid 28177411)
23. Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 2006;111:652-673. (Pubitemid 44137382)
24. Wallukat G. The beta-adrenergic receptors. Herz 2002;27:683-690.
25. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997;13: 375-423.
26. Takahashi K, Mulliken JB, Kozakewich HPW, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-2364. (Pubitemid 24177146)
27. Hermans DJJ, van Beynum IM, van der Vijver RJ, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. J Pediatr Hematol Oncol 2011;33:e171-e173.
28. Moss HB, Sines DT, Blatt J, et al. Epithelioid hemangioma responsive to oral propranolol. Ophthal Plast Reconstr Surg 2011; e-pub ahead of print.
29. Truong MT, Perkins JA, Messner AH, et al. Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. Int J Pediatr Otorhinolaryngol 2010;74:1043-1048.
30. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42.